Across TCGA pan-cancer cohorts, IGLV8-61 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated IGLV8-61 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.
The strongest signal is observed in thyroid carcinoma (THCA), where higher IGLV8-61 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGLV8-61 expression acts as an unfavorable survival marker.
THCA, LUAD, and LUSC are the cancer types where IGLV8-61 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.